-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTC:COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr. Hysek AG toward an exclusive partnership for the import and distribution of licensed MDMA and psilocybin products into Australia, of which detailed commercial aspects are expected by this August 31.
The Biel-based pharmacy is a Good Manufacturing Practice (GMP)-compliant facility manufacturing MDMA, synthetic psilocybin and LSD under Pharma GMP conditions and is authorized by the Swiss medicine agency (Swissmedic) and the country's Federal Office of Public Health (FOPH.)
Founder Dr. Cedric Hysek works closely with Dr. Matthias Liechti, a University Hospital Basel (UHB) professor involved with the Swiss limited-use psychedelics program and leading several MindMed (NASDAQ:MNMD)-backed studies.
Following Australia's new legal framework for psychedelic-assisted therapies effective in July, Creso Pharma will provide import infrastructure, warehouse and product distribution through its wholly-owned subsidiary Health House International (HHI.)
HHI holds wholesale and manufacturer licenses aligned with TGA guidelines and will apply for an import permit through the country's Office of Drug Control for this specific import and involving clinical purposes only.
The Creso-HHI team says they are discussing with several Australian stakeholders including GPs, pharmacists and practicing psychiatrists to form alliances with health professionals willing to enter the sector.
Creso Pharma CEO and managing director William Lay says the new LOI "sets out the terms and parameters" for the licensed import and distribution to Australia of approved MDMA and psilocybin products "manufactured by one of the world's foremost practitioners in this space."
Lay said Dr. Hysek is "undoubtedly a pioneer" in applying MDMA and psilocybin treatments for better patient outcomes, collaborating with Swiss regulators and university researchers. Hysek said he hopes the new deal will result in benefitting from the Swiss knowledge and experience toward making the Australian healthcare industry work for the patients' benefit.
See also: Building Australia's Psychedelics Industry: A New Joint Venture And Why It's Important
That intention is echoed by Dr. Liechti, who says the knowledge from the 2015-and-running Swiss collaborative approach between federal regulators, researchers and medical professionals for "improved patient outcomes" has the potential to be shared "with both the TGA and key stakeholders in the Australian healthcare industry" toward developing "similarly effective programs" in the country's market.
"As a research partner of the Swiss limited-use program since inception, I have a direct interest in assisting in the efficient and regulated rollout of these medical applications to other jurisdictions and would embrace the opportunity to work closely with the Australian medical industry towards that goal," Liechti concluded.
Photo: Benzinga edit with photo by RF_studio on Pexels and anaterate on Pixabay.
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTC:COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr. Hysek AG toward an exclusive partnership for the import and distribution of licensed MDMA and psilocybin products into Australia, of which detailed commercial aspects are expected by this August 31.
总部位于澳大利亚的大麻和迷幻药公司 Creso Pharma 有限公司 (场外交易代码:COPHF) 签署了一份意向书 (LOI)与瑞士药房合作 Apotheke Dr. Hysek 建立独家合作伙伴关系,向澳大利亚进口和分销获得许可的摇头丸和psilocybin产品,其详细的商业方面预计将在今年8月31日之前公布。
The Biel-based pharmacy is a Good Manufacturing Practice (GMP)-compliant facility manufacturing MDMA, synthetic psilocybin and LSD under Pharma GMP conditions and is authorized by the Swiss medicine agency (Swissmedic) and the country's Federal Office of Public Health (FOPH.)
这家总部位于比尔的药房是符合良好生产规范(GMP)的工厂,在药品GMP条件下生产摇头丸、合成psilocybin和LSD,并获得了瑞士药品管理局(Swissmedic)和该国联邦公共卫生办公室(FOPH。)的授权
Founder Dr. Cedric Hysek works closely with Dr. Matthias Liechti, a University Hospital Basel (UHB) professor involved with the Swiss limited-use psychedelics program and leading several MindMed (NASDAQ:MNMD)-backed studies.
创始人 Cedric Hysek 博士 紧密合作 马蒂亚斯·列奇蒂博士,巴塞尔大学医院(UHB)教授,参与瑞士限量使用迷幻药计划,并领导了几项由MindMed(纳斯达克股票代码:MNMD)支持的研究。
Following Australia's new legal framework for psychedelic-assisted therapies effective in July, Creso Pharma will provide import infrastructure, warehouse and product distribution through its wholly-owned subsidiary Health House International (HHI.)
继澳大利亚迷幻辅助疗法的新法律框架于7月生效之后,Creso Pharma将通过其全资子公司Health House International(HHI.)提供进口基础设施、仓库和产品分销
HHI holds wholesale and manufacturer licenses aligned with TGA guidelines and will apply for an import permit through the country's Office of Drug Control for this specific import and involving clinical purposes only.
HHI持有符合TGA指导方针的批发和制造商许可证,并将通过该国的药物管制办公室为这种特定进口申请进口许可证,仅涉及临床目的。
The Creso-HHI team says they are discussing with several Australian stakeholders including GPs, pharmacists and practicing psychiatrists to form alliances with health professionals willing to enter the sector.
Creso-HHI团队表示,他们正在与包括全科医生、药剂师和执业精神科医生在内的几位澳大利亚利益相关者进行讨论,以与愿意进入该领域的卫生专业人员结成联盟。
Creso Pharma CEO and managing director William Lay says the new LOI "sets out the terms and parameters" for the licensed import and distribution to Australia of approved MDMA and psilocybin products "manufactured by one of the world's foremost practitioners in this space."
Creso Pharma 首席执行官兼董事经理威廉·莱 说,新的意向书 “规定了许可向澳大利亚进口和分销经批准的摇头丸和psilocybin产品的条款和参数”,“由该领域世界上最重要的从业者之一制造”。
Lay said Dr. Hysek is "undoubtedly a pioneer" in applying MDMA and psilocybin treatments for better patient outcomes, collaborating with Swiss regulators and university researchers. Hysek said he hopes the new deal will result in benefitting from the Swiss knowledge and experience toward making the Australian healthcare industry work for the patients' benefit.
莱说,Hysek博士 “无疑是应用摇头丸和psilocybin治疗以改善患者预后的先驱”,他与瑞士监管机构和大学研究人员合作。Hysek说,他希望这项新协议能够从瑞士的知识和经验中受益,使澳大利亚的医疗保健行业为患者的利益服务。
See also: Building Australia's Psychedelics Industry: A New Joint Venture And Why It's Important
另见:建设澳大利亚的迷幻药产业:一家新的合资企业及其重要性
That intention is echoed by Dr. Liechti, who says the knowledge from the 2015-and-running Swiss collaborative approach between federal regulators, researchers and medical professionals for "improved patient outcomes" has the potential to be shared "with both the TGA and key stakeholders in the Australian healthcare industry" toward developing "similarly effective programs" in the country's market.
Liechti博士也赞同这一意图,他说,联邦监管机构、研究人员和医疗专业人员为了 “改善患者预后” 而于2015年推出的瑞士合作方针所获得的知识有可能 “与TGA和澳大利亚医疗保健行业的主要利益相关者” 共享,以在该国市场上制定 “类似有效的计划”。
"As a research partner of the Swiss limited-use program since inception, I have a direct interest in assisting in the efficient and regulated rollout of these medical applications to other jurisdictions and would embrace the opportunity to work closely with the Australian medical industry towards that goal," Liechti concluded.
Liechti总结说:“作为瑞士有限用途计划的研究合作伙伴,我有直接的兴趣是协助在其他司法管辖区高效和监管地推出这些医疗应用,并将抓住机会与澳大利亚医疗行业密切合作以实现这一目标。”
Photo: Benzinga edit with photo by RF_studio on Pexels and anaterate on Pixabay.
照片:Benzinga 在 Pexels 上用 rf_Studio 的照片进行编辑,在 Pixabay 上使用 anaterate 进行编辑。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧